The FDA's drug approvals database lists a supplement to Eli Lilly's new drug application for tirzepatide marketed as Zepbound (NDA217806), recorded on 12 October. The listing does not say what the supplement changes; supplements cover anything from manufacturing and labelling to new indications.
Until the label change is published, there is nothing to alter in prescribing. Watch for an updated label that would explain the scope.
- This is a supplement record without published details; it does not establish a new indication.
- Check the updated label once it is posted before changing practice.
- Regulatory status in India is set separately by CDSCO.
Why it matters
Tirzepatide is prescribed widely, and label changes may affect dosing, indications or warnings.
Don't overread it
A supplement listing is not by itself an approval of anything new.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free